代表性论文（近5年）
1. Li W, Zhang H, Xiang Q*, Cui Y. Does repeat revascularization introduce bias for reducing mortality in antiplatelet therapy group? J Am Coll Cardiol 2021 Nov 16;78(20):e171. (Corresponding author) Q1, IF 24.00
2. Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, Gu Y, Zhao N, Xiang Q*, Cui Y*. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023 Jan 2;8(1):1. doi: 10.1038/s41392-022-01259-6. (Co-corresponding author) Q1, IF 39.3
3. Xiang Q, Pang X, Liu Z, Yang G, Tao W, Pei Q, Cui Y. Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic. Pharmacol Ther. 2019;203:107393. Q1, IF 13.5
4. Xiang Q, Wu W, Zhao N, Li C, Xu J, Ma L, Zhang X, Xie Q, Zhang Z, Wang J, Xu W, Zhao X, Cui Y. The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations. Asian J Pharm Sci. 2020;15(2):264-272. Q1, IF 10.2
5. Liu Z, Xiang Q*, Zhao X, Wang Z, Mu G, Xie Q, Zhou S, Chen S, Hu K, Xu J, Ma L, Cui Y. Candidate gene and pathway analyses identifying genetic variations associated with prasugrel pharmacokinetics and pharmacodynamics. Thromb Res. 2018;173:27-34. (Corresponding author) Q1, IF 7.5
6. Xiang Q, Zhang HX, Wang Z, Liu ZY, Xie QF, Hu K, Zhang Z, Mu GY, Ma LY, Jiang J, Cui YM. The predictive value of circulating microRNAs for venous thromboembolism diagnosis: A systematic review and diagnostic meta-analysis. Thromb Res. 2019 Sep;181:127-134. Q1, IF 7.5
7. Xiang Q#, Wang Z#, Mu G, Xie Q, Liu Z, Zhou S, Zhang H, Wang Z, Jiang J, Hu K, Zhang Y, Zhao Z, Yuan D, Guo L, Wu T, Zhang J, Wang N, Xiang J, Gu Z, Sun J, Cui Y*. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study. Clin Transl Med. 2023;13(5):e1263.（并列第一作者）Q1, IF 10.6
8. Xiang Q#, Xie Q#, Liu Z, Mu G, Zhang H, Zhou S, Wang Z, Wang Z, Zhang Y, Zhao Z, Yuan D, Guo L, Wang N, Xiang J, Song H, Sun J, Jiang J, Cui Y. Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study[J]. Clin Transl Med, 2022, 12(12): e1104.（并列第一作者）Q1, IF 10.6
9. Xiang Q, Cui Y. Letter by Xiang and Cui Regarding Article, "Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation".Stroke. 2020 Jan;51(1):e9. Q1, IF 10.3
10. Liu ZY, Sun MX, Hua MQ, Zhang HX, Mu GY, Zhou S, Wang Z, Xiang Q*, Cui YM*. New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF. Front Immunol. 2023 Feb 28;14:1098665. (Co-corresponding author) Q1, IF 7.3
11. Liu Z, Li L, Zhang H, Pang X, Qiu Z, Xiang Q*, Cui Y*. Platelet factor 4(PF4) and its multiple roles in diseases. Blood Rev. 2023 Nov 23:101155. doi: 10.1016/j.blre.2023.101155. Epub ahead of print. (Co-corresponding author) Q1, IF 7.4
12. Liu ZY, Sun MX, Hua MQ, Zhang HX, Mu GY, Zhou S, Wang Z, Xiang Q*, Cui Y*. New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF. Front Immunol. 2023 Feb 28;14:1098665. (Co-corresponding author) Q1, IF 7.3
13. Zhang H, Liu Z, Mu G, Wang Z, Zhou S, Xie Q, Ma L, Wang Z, Hu K, Gong Y, Jiang J, Xiang Q*, Cui Y*. Diagnostic performance of coagulation indices for direct oral anticoagulant concentration. Thromb Res. 2020 Nov;195:171-179. (Co-corresponding author) Q1, IF 7.5
主要知识产权
1. 崔一民，向倩，王哲，邱志维，翟小田；抗血小板聚集多肽、其制备方法及应用；专利号：ZL 2023 1 1434040.2，授权公告日：2024年02月06日，授权公告号：CN 117143194 B
2. 向倩，崔一民，种珊，刘志艳，母光妍，王哲；专利名称 ALPK2，ITGA11，ESYT1，CDH17在预测药物出血中的应用，专利申请号2023110946998。
3. 崔一民，向倩，刘志艳，母光妍，周双，王哲，张涵煦；AHNAK2 的SNP 标志物在抗血栓药物治疗血栓疗效预测中的应用，2023-02-03，中国，ZL202211365044.5（发明专利）.
4. 崔一民，向倩，王哲，胡琨，常国栋，PEAR1基因突变试剂盒及其应用，申请号 202011610119，申请日：2020.12.29
5. 崔一民，向倩，刘志艳，母光妍，一种血小板因子4蛋白/聚乙烯磺酸复合物及其制备方法与应用，申请号 202010386443.4，申请日：2020.05.09
6. 崔一民，向倩, 刘志艳，母光妍，徐为人，李川，一种可用于辅助氯吡格雷精准用药的PRKG1基因SNP标志物，申请号 201910225807.8，申请日：2019.3.25
7. 崔一民，向倩, 刘志艳，母光妍，徐为人，李川，一种可用于辅助氯吡格雷精准用药的ITGB1基因SNP标志物，申请号 201910225359.1，申请日：2019.3.25
8. 崔一民，向倩，母光妍，刘志艳，张卓，刘亚欧，北京大学第一医院；上物临床试验电子病例采集系统软件V3.2， 2023SR0236858，继受取得，全部权利，2023-02-14（软件著作权）.
9. 思派（北京）网络科技有限公司，崔一民，向倩，谢秋芬，母光妍，刘志艳，抗凝药物规范化使用项目数据库系统V1.0，开发完成日期：2018.3.1，登记号：2019SR0711423
10. 思派（北京）网络科技有限公司，崔一民，向倩，谢秋芬，母光妍，刘志艳，乳腺癌患者管理系统V1.0，开发完成日期：2018.3.1，登记号：2019SR0711419
